Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.
If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.
Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD ( FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity ( SELECT trial) .
Why this rating
Based on multiple large-scale Phase 3 clinical trials (FLOW, SELECT, LEADER, SUSTAIN-6) with published results and regulatory approvals.
Source
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva et al. · Clinical Kidney Journal · 2024
DOI 10.1093/ckj/sfae296
More from this paper
- GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.Good
- Lifestyle interventions alone are difficult to maintain long-term for weight loss in patients with T2DM and CKD, whereas GLP-1 RAs offer a pharmacological alternative with proven metabolic and organ protection benefits.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →